Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Current Deferred Revenue (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Current Deferred Revenue readings, the most recent being $684000.0 for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue fell 95.72% to $684000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $684000.0, a 95.72% decrease, with the full-year FY2025 number at $716000.0, down 99.25% from a year prior.
  • Current Deferred Revenue hit $684000.0 in Q1 2026 for Atara Biotherapeutics, down from $716000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $123.2 million in Q1 2024 to a low of $684000.0 in Q1 2026.
  • Median Current Deferred Revenue over the past 5 years was $11.6 million (2023), compared with a mean of $37.5 million.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 1140.97% in 2024 and later crashed 99.25% in 2025.
  • Atara Biotherapeutics' Current Deferred Revenue stood at $8.0 million in 2022, then soared by 872.91% to $77.8 million in 2023, then grew by 22.17% to $95.1 million in 2024, then crashed by 99.25% to $716000.0 in 2025, then dropped by 4.47% to $684000.0 in 2026.
  • The last three reported values for Current Deferred Revenue were $684000.0 (Q1 2026), $716000.0 (Q4 2025), and $1.0 million (Q3 2025) per Business Quant data.